0156T0 — HL Genomics Cashflow Statement
0.000.00%
Last trade - 00:00- KR₩56bn
- KR₩18bn
- KR₩29bn
Annual cashflow statement for HL Genomics, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Net Income/Starting Line | 9,115 | 10,438 | 10,544 |
| Depreciation | |||
| Amortisation | |||
| Non-Cash Items | -146 | -1,031 | -716 |
| Unusual Items | |||
| Other Non-Cash Items | |||
| Changes in Working Capital | 664 | -2,020 | -2,896 |
| Change in Accounts Receivable | |||
| Change in Inventories | |||
| Change in Other Assets | |||
| Change in Accounts Payable | |||
| Change in Other Liabilities | |||
| Net Change in Other Assets & Liabilities | |||
| Other Operating Cash Flow | |||
| Cash from Operating Activities | 9,633 | 8,734 | 8,337 |
| Capital Expenditures | -9,812 | -8,987 | -4,526 |
| Purchase of Fixed Assets | |||
| Purchase / Acquisition of Intangibles | |||
| Other Investing Cash Flow Items | 3,541 | -1,092 | -2,551 |
| Sale of Fixed Assets | |||
| Sale/Maturity of Investment | |||
| Purchase of Investments | |||
| Cash from Investing Activities | -6,270 | -10,079 | -7,076 |
| Net Issuance / Retirement of Debt | |||
| Cash from Financing Activities | -200 | -457 | -486 |
| Foreign Exchange Effects | |||
| Beginning Cash Balance | |||
| Ending Cash Balance | |||
| Net Change in Cash | 3,145 | -1,778 | 747 |